Lineage Cell Therapeutics
LCTX
68 hedge funds and large institutions have $134M invested in Lineage Cell Therapeutics in 2015 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 12 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 10
36% more capital invested
Capital invested by funds: $98.6M → $134M (+$35.3M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4.8% less ownership
Funds ownership: 49.66% → 44.85% (-4.8%)
8% less funds holding
Funds holding: 74 → 68 (-6)
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
82% less call options, than puts
Call options by funds: $284K | Put options by funds: $1.55M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
+$5.93M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$507K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$506K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$309K |
| 5 |
State Street
Boston,
Massachusetts
|
+$234K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$1.62M |
| 2 |
Jane Street
New York
|
-$376K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$192K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$132K |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$102K |
LCTX Hedge Fund Activity: Q4 2015 in Review
68 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q4 2015, worth a combined $134M — up 36% from $98.6M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of LCTX and 6 opened new positions — a net loss of 6 holders — while 10 trimmed existing stakes and 25 added.
The largest buyer was Broadwood Capital, adding an estimated $5.93M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $1.62M sold.
- 68 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q4 2015, down from 74 in Q3 2015.
- Funds reported $134M of Lineage Cell Therapeutics stock for Q4 2015, up 36% quarter-over-quarter.
- 6 funds opened new Lineage Cell Therapeutics positions in Q4 2015 and 12 closed out, a net change of -6 holders.
- The largest Lineage Cell Therapeutics buyer in Q4 2015 was Broadwood Capital, an estimated $5.93M added.
- The largest Lineage Cell Therapeutics seller in Q4 2015 was Consonance Capital Management, an estimated $1.62M sold.
Based on aggregated 13F filings for Q4 2015.